Proneness to formation of tight and rigid fibrin gel structures in men with myocardial infarction at a young age

Thrombosis and Haemostasis

Volumn 76, Issue 4, 1996, Pages 535-540

  Fatah, Kamaran ^a   Silveira, Angela ^a   Tornvall, Per ^a   Karpe, Fredrik ^a   Blombäck, Margareta ^a   Hamsten, Anders ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; FIBRIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; FIBRIN FORMATION; FIBRINOLYSIS; HEART INFARCTION; HUMAN; HUMAN TISSUE; LIPOPROTEIN BLOOD LEVEL; MALE; NORMAL HUMAN; ONSET AGE; PERMEABILITY; PHYSICAL PHENOMENA; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0029842962     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1650618     Document Type: Article

References (26)

1. Blombäck B, Bannerjee D, Carlsson K, Hamsten A, Hessel B, Procyk R, Silveira A, Zacharski L. Native fibrin gel networks and factors influencing their formation in health and disease. In: Fibrinogen, Thrombosis, Coagulation, and Fibrinolysis. Liu CY, Chien S, eds. Plenum Press, New York 1991: 1-23.
2. Blombäck B, Carlsson K, Hessel B, Liljeborg A, Procyk R, Åslund N. Native fibrin gel networks observed by 3D microscopy, permeation and turbidity. Biochim Biophys Acta 1989; 997: 96-110.
3. Fatah K, Hamsten A, Blombäck B, Blombäck M. Native fibrin gel network properties and coronary heart disease: relations to plasma fibrinogen, acute phase protein, serum lipoproteins and coronary atherosclerosis. Thromb Haemost 1992; 68: 130-5.
4. Hamsten A, Blombäck M, Wiman B, Svensson J, Szamosi A, de Faire U, Mettinger L. Haemostatic function in myocardial infarction. Br Heart J 1986; 55: 58-66.
5. Blombäck B, Carlsson K, Fatah K, Hessel B, Procyk R. Fibrin in human plasma: gel architectures governed by rate and nature of fibrinogen activation. Thromb Res 1994; 75: 521-38.
6. Blombäck B, Okada M. Fibrin gel structure and clotting time. Thromb Res 1982; 25: 51-70.
7. Bergström K, Blombäck B, Kleen G. Studies on the plasma fibrinolytic activity in a case of liver cirrhosis. Acta Med Scand 1963; 8: 418-24.
8. Chmielewska J, Rånby M, Wiman B. Evidence for a rapid inhibitor to tissue plasminogen activator in plasma. Thromb Res 1983; 31: 427-36.
9. Carlson K. Lipoprotein fractionation. J Clin Path 1973; 26: 32-7.
10. Snedecor GW, Cochran WG. Statistical Methods. Iowa State University Press, Ames IA 1978.
11. Princkard RN, Hawkins D, Farr RS. In vitro acetylation of plasma proteins, enzymes and DNA by aspirin. Nature 1968; 219: 68-9.
12. Björnsson TD, Schneider DE, Berger H Jr. Aspirin acetylates fibrinogen and enhances fibrinolysis. Fibrinolytic effect is independent of changes in plasminogen activator levels. J Pharm Exp Ther 1989; 250: 154-61.
13. Fatah K, Beving H, Albåge A, Ivert T, Blombäck M. Acetylsalicylic acid may protect the patient by increasing fibrin gel porosity. Is withdrawing of treatment harmful to the patient? Eur Heart J 1996; 17.
14. Siebenlist KR, Mosesson MW. Progressive cross-linking of fibrin γ-chains increases resistance to fibrinolysis. J Biol Chem 1994; 269: 28414-9.
15. Sakata Y, Mimuro J, Aoki N. Differential binding of plasminogen to cross-linked and noncrosslinked fibrins: its significance in hemostatic defect in factor XIII deficiency. Blood 1984; 63: 1393-401.
16. Yonekawa O, Voskuilen M, Nieuwenhuizen W. Localization in the fibrinogen γ-chain of a new site that is involved in the acceleration of the tissue-type plasminogen activator-catalysed activation of plasminogen. Biochem J 1992; 283: 187-91.
17. Jansen J, Haverkate F, Koopman J, Nieuwenhuis H, Kluft C, Boschman T. Influence of factor XIIIa on human whole blood clot lysis in vitro. Thromb Haemost 1987; 57: 171-5.
18. van Giezen JJJ, Minkema J, Bouma BN, Jansen JWCM. Cross-linking of alpha 2-antiplasmin to fibrin is a key factor in regulating blood clot lysis: species differences. Blood Coag Fibrinol 1993; 4: 869-75.
19. Duguid JB. Thrombosis as a factor in the pathogenesis of coronary atherosclerosis. J Path Bact 1946; 58: 207-12.
20. Woolf N. Thrombosis and atherosclerosis. Br Med Bull 1978; 34: 137-42.
21. Smith EB, Staples EM, Dietz HS, Smith RH. Role of endothelium in sequestration of lipoprotein and fibrinogen in aortic lesions, thrombi and graft pseudointima. Lancet 1979; ii: 812-6.
22. Smith SB, Staples EM. Haemostatic factors in human aortic intima. Lancet 1981; i: 1171-9.
23. Hessel B, Silveira AMV, Carlsson K, Oksa H, Rasi V, Vahtera E, Procyk R, Blombäck B. Fibrinogenemia Tampere - a dysfibrinogenemia with defective gelation and thromboembolic disease. Thromb Res 1995; 78: 323-39.
24. Gabriel DA, Muga K, Boothroyd EM. The effect of fibrin structure on fibrinolysis. J Biol Chem 1992; 267: 24259-63.
25. Collet J-P, Soria J, Mirshahi M, Hirsch M, Dagonnet FB, Caen J, Soria C. Dusart syndrome: a new concept of the relationship between fibrin clot architecture and fibrin clot degradability: Hypofibrinolysis related to an abnormal clot structure. Blood 1993; 82: 2462-9.
26. Dawson S, Henney A. The status of PAI-1 as a risk factor for arterial and thrombotic disease: a review. Atherosclerosis 1992; 95: 105-17.